AllSci News

Systematic, data-driven science coverage · Monday, September 7, 2026
The AllSci BriefFree, systematic R&D and deal news. Daily.
Most Read
Business

Keymed licenses approved IL-4Ralpha mAb stapokibart to Singapore firm Aeira for 18 Asian markets

Keymed licenses approved IL-4Ralpha mAb stapokibart to Singapore firm Aeira for 18 Asian markets
Development

Acoramidis shows signs of cardiac remodeling reversal in ATTR-CM CMR analysis

Acoramidis shows signs of cardiac remodeling reversal in ATTR-CM CMR analysis
Development

Soufflé joins DUX4 race in FSHD with muscle-targeted siRNA conjugate

Soufflé joins DUX4 race in FSHD with muscle-targeted siRNA conjugate
Regulatory & Policy

Hengrui files Kailera-partnered oral GLP-1 for China approval in obesity and diabetes

Hengrui files Kailera-partnered oral GLP-1 for China approval in obesity and diabetes
Development

Five-year Camzyos data show sustained oHCM benefit as aficamten competition emerges

Five-year Camzyos data show sustained oHCM benefit as aficamten competition emerges
Editor’s Picks
Stoke, Biogen report four-year durability for Dravet therapy zorevunersenDevelopment

Stoke, Biogen report four-year durability for Dravet therapy zorevunersen

· 3 min read
Peking University engineers proteins that switch on in nitric oxide-rich tissuesDiscovery

Peking University engineers proteins that switch on in nitric oxide-rich tissues

· 3 min read
Argo's siRNA therapy cuts HAE attack rates 83–96% in small Phase II studyDevelopment

Argo's siRNA therapy cuts HAE attack rates 83–96% in small Phase II study

· 3 min read
Latest NewsView all news →
Intellia secures USD 400m non-dilutive debt facility ahead of lonvo-z commercial launch
Business

Intellia secures USD 400m non-dilutive debt facility ahead of lonvo-z commercial launch

Massachusetts-based Intellia Therapeutics, Inc. (Nasdaq: NTLA) announced a non-dilutive senior secured term loan facility of up to USD 400 million with...

3d agoAcepodia wins FDA clearance for dual-payload GPC3 ADC in liver cancer
Regulatory & Policy

Acepodia wins FDA clearance for dual-payload GPC3 ADC in liver cancer

California- and Taiwan-based Acepodia (TWSE: 6976) has received US FDA clearance to begin Phase I testing of ACE723, a GPC3-targeted dual-payload...

3d agoNeuShen lands USD 80m+ Series B for CNS expansion
Business

NeuShen lands USD 80m+ Series B for CNS expansion

With three central nervous system (central nervous system, or CNS) clinical-stage programs under way up to Phase II, China-based NeuShen Therapeutics...

3d ago
Development

Innovent takes once-weekly oral GLP-1 into Phase I

Innovent Biologics (HKEX: 01801) has registered a Phase I study of IBI3042, an oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist...

3d agoDimerix secures AUD 34m non-dilutive funding through Phase III kidney disease trial readout
Business

Dimerix secures AUD 34m non-dilutive funding through Phase III kidney disease trial readout

Australia-based Dimerix Limited (ASX: DXB) announced a non-dilutive loan facility of AUD 34 million (USD 23.9 million) with a syndicate of Australian and US...

3d agoFDA requests public input on botanical drug product development pathways
Regulatory & Policy

FDA requests public input on botanical drug product development pathways

The FDA has issued a Request for Information (RFI) seeking public comment on how to advance the development of FDA botanical drug products — therapeutics...

3d agoSuperluminal raises USD 60m Series B to take rare obesity drug into Phase I
Business

Superluminal raises USD 60m Series B to take rare obesity drug into Phase I

Boston-based Superluminal Medicines has closed an oversubscribed USD 60 million Series B financing round to advance its lead small-molecule melanocortin-4...

3d agoENA expands antiviral nasal spray INNA-051 into asthma patients with grant backing
Business

ENA expands antiviral nasal spray INNA-051 into asthma patients with grant backing

Australia-based ENA Respiratory has received AUD 2.98 million (USD 1.9 million) from Biointelect Venturer to fund the first study of its INNA-051 antiviral...

3d ago
The AllSci BriefFree, systematic R&D and deal news. Daily.
Soufflé joins DUX4 race in FSHD with muscle-targeted siRNA conjugate
Development

Soufflé joins DUX4 race in FSHD with muscle-targeted siRNA conjugate

Massachusetts-based Soufflé Therapeutics, Inc. has registered a Phase I/II clinical trial of SFL-0821, an antibody-siRNA conjugate designed to silence DUX4...

3d agoChina approves Milestone/Everest's Cardamyst nasal spray for acute PSVT
Regulatory & Policy

China approves Milestone/Everest's Cardamyst nasal spray for acute PSVT

China's National Medical Products Administration (NMPA) has approved Cardamyst (etripamil) nasal spray for the treatment of paroxysmal supraventricular...

3d agoCipla joins Keytruda biosimilar race with Qilu deal
Business

Cipla joins Keytruda biosimilar race with Qilu deal

India-based Cipla Limited (BSE: 500087; NSE: CIPLA) has secured exclusive US commercialization rights for QL2107, a biosimilar to pembrolizumab (Keytruda),...

3d agoThryv expands SGK1 platform into neurodegeneration with Spanish academic license
Business

Thryv expands SGK1 platform into neurodegeneration with Spanish academic license

Montréal-based Thryv Therapeutics Inc. has licensed an exclusive, worldwide patent and know-how rights to a structurally distinct class of SGK1 inhibitors...

3d agoAbbVie closes USD 10.9b Apogee purchase for IL-13 zumilokibart
Business

AbbVie closes USD 10.9b Apogee purchase for IL-13 zumilokibart

AbbVie (NYSE: ABBV) completed its acquisition of Apogee Therapeutics on September 3, 2026, paying USD 135.11 per share in cash for a total equity value of...

3d agoPfizer hands former Seagen ADC to Medicus in USD 1b-plus deal
Business

Pfizer hands former Seagen ADC to Medicus in USD 1b-plus deal

Medicus Pharma Ltd. (Nasdaq: MDCX) has licensed worldwide rights to Pfizer's PF-08046031 (CD228V), an early clinical-stage antibody-drug conjugate (ADC)...

3d agoChina approves two homegrown long-acting RSV antibodies for infants
Regulatory & Policy

China approves two homegrown long-acting RSV antibodies for infants

China's National Medical Products Administration (NMPA) has approved two domestically developed long-acting monoclonal antibodies for the prevention of...

3d ago